NCT02806726 is a NA clinical trial of iDesign 1.3-PRESBY treatment in Presbyopia, sponsored by Abbott Medical Optics.

Who is sponsoring NCT02806726?

NCT02806726 is sponsored by Abbott Medical Optics.

What drugs are being tested in NCT02806726?

Interventions in NCT02806726: iDesign 1.3-PRESBY treatment, iDesign 1.3 treatment.

What condition does NCT02806726 study?

NCT02806726 studies Presbyopia, Myopia.

Is NCT02806726 still recruiting?

NCT02806726 is currently terminated. Last updated 4 February 2025.

Are results published for NCT02806726?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-02-04 · How we verify

NCT02806726

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Investigation iDesign System With 1.3-PRESBY Treatment and STAR S4 IR™ Excimer Laser System

Terminated NA Results posted Last updated 4 February 2025

What this trial tests

NA trial testing iDesign 1.3-PRESBY treatment in Presbyopia in 42 participants. Terminated before completion.

Timeline

13 July 2016

Primary endpoint
9 November 2017

9 November 2017

Quick facts

Lead sponsor	Abbott Medical Optics
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	42
Start date	13 July 2016
Primary completion	9 November 2017
Estimated completion	9 November 2017

Drugs / interventions tested

iDesign 1.3-PRESBY treatment
iDesign 1.3 treatment

Conditions studied

Presbyopia — all drugs for Presbyopia →
Myopia — all drugs for Myopia →

Sponsor

Abbott Medical Optics

Who can join

45 and older, any sex, with Presbyopia or Myopia. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Monocular Distance Corrected Intermediate Visual Acuity (DCIVA) at 67 cm Primary · 6 months

Mean distance corrected intermediate visual acuity (DCIVA) for presbyT-LASIK treatments (test) was compared to iDesign CustomVue treatments (control).

Group	Value	95% CI
iDesign 1.3-Presby Treatment (Experimental)	0.03	-0.1 – 0.16
iDesign CustomVue Treatments (Control)	0.1	-0.02 – 0.22

Monocular Distance Corrected Near Visual Acuity (DCNVA) AT 40 cm Secondary · 6 months

Mean distance corrected near visual acuity (DCNVA) for PresbyT-LASIK treatments (test) was compared to iDesign CustomVue treatments (control).

Group	Value	95% CI
iDesign 1.3-Presby Treatment (Experimental)	0.25	0.16 – 0.34
iDesign CustomVue Treatments (Control)	0.35	0.1 – 0.6

Adverse events — posted to ClinicalTrials.gov

Time frame: 6 months. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

All Study Participants

Serious: 0/7 (0%)

Deaths: 0/7

Other adverse events (2 terms — click to expand)

Reaction	System	All Study Participants
Diffuse lamellar keratitis	Eye disorders	—
Mild Headache	General disorders	—

Data from ClinicalTrials.gov NCT02806726 adverse events section.

Sponsor's own description

A prospective study to evaluate the feasibility of a new treatment algorithm to increase depth of focus after wavefront-guided LASIK correction of myopic refractive errors with the iDesign Advanced Wavescan Studio™ System and Star S4 IR™ Excimer Laser System. The purpose of this study is to determine whether wavefront-guided LASIK correction of myopic refractive errors with CustomVue combined with iDesign 1.3-PRESBY (presbyT-LASIK) treatments mitigate the effects of presbyopia by increasing the depth of focus compared to iDesign CustomVue treatments.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Presbyopia

Currently open trials in the same condition.

NCT07444658 — Performance of Two Daily Disposable Multifocal Contact Lenses · NA · recruiting
NCT07284966 — Comfort and Vision With TOTAL30 Multifocal Lenses · recruiting
NCT07077967 — Luminous Efficiency Function V(λ)' of Patients That Underwent Pseudophakic Presbyopic Corrections With EDOF IOLs · recruiting
NCT07113210 — Quality of Life in Presbyopic Patients Who Are Treated With Qlosi · Phase 4 · recruiting
NCT06948357 — Efficacy and Safety of BRIMOCHOL PF and CARBACHOL PF in Chinese Presbyopia Patients · Phase 2 · recruiting

Other Abbott Medical Optics trials

Trials by the same sponsor.

NCT03372434 — Clinical Investigation of the Next-Generation Intraocular Lenses · NA · completed
NCT03111550 — Clinical Investigation of the Next-Generation Intraocular Lens · NA · completed
NCT02782676 — Clinical Investigation of the Bacterially-Derived Healon5 Ophthalmic Viscosurgical Device (OVD) · NA · completed
NCT02649842 — Post-Approval Study of the TECNIS® Toric Extended Cylinder Range Intraocular Lens (IOL) · NA · completed
NCT02675751 — Prospective S&E Study of Wavefront-guided PRK for Myopia With iDesign Advanced Wavescan Studio™ System and Star S4 IR™ · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02806726 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Abbott Medical Optics
Last refreshed: 4 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02806726.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing